

Lund, February 12th, 2026
EQL Pharma AB (publ)
556713-3425

Nomination committee for the 2026 Annual General Meeting

In accordance with the instructions of the Nomination Committee in EQL Pharma, the Nomination Committee shall be convened by the Chairman of the Board and shall consist of a representative for each of the three largest shareholders in terms of votes who wish to appoint a Nomination Committee member. The composition of the Nomination Committee is based on shareholder statistics from Euroclear Sweden AB as of the last banking day in December and other reliable information on ownership that has been made known to the company at the same time.

Based on the above, the Nomination Committee for the 2026 Annual General Meeting, which will be held in Lund on 20 August 2026, has been determined to consist of:

- Christer Fähræus (appointed by Fårö Capital AB),
- Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and
- Sten Irwe.

The Nomination Committee's proposal will be presented in the notice of the 2026 Annual General Meeting and published on the company's website, www.eqlpharma.com.

The Nomination Committee's tasks include preparing and submitting proposals to the upcoming Annual General Meeting for: election of the Chairman of the Annual General Meeting; election of the Chairman and other members of the Board; board fees divided between the Chairman and other members and any remuneration for committee work; election of the auditor and remuneration to him/her; and principles for the appointment of the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee are encouraged to send an e-mail to info@eqlpharma.com. In order for the proposals to be considered by the Nomination Committee, they must be submitted well in advance of the Annual General Meeting.

For further information, please contact:
Axel Schörling

CEO, EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 47 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.